COMPANY

Nura Bio

HQ: South San Francisco, CA source · nurabio.com ↗

We are developing small molecule inhibitors of SARM1 for the treatment of peripheral, central and ocular nervous system disorders. From company website Source · Oct 13, 2026

Keywords: small molecule inhibitors sarm1 Amyotrophic Lateral Sclerosis NB-4746 (Dose TBD)

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

1Trials (company is sponsor)

Raises and deals from press releases

Raise Series B · $73.8M · announced Jun 22, 2026 Company release ↗
Source quote
- Jun 22, 2026 · Company release ↗
  “(Nura Bio), a clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, today announced the completion of a $73.8M Series B financing and the advancement of its two clinical-stage SARM1 inhibitor programs”
Raise Series A · $68M · announced Sep 17, 2024 Company release ↗
Source quote
- Sep 17, 2024 · Company release ↗
  “Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million”

Raises announced in these releases: $141.8M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Jun 22, 2026 Raise Series B · $73.8M source ↗
Mar 4, 2026 Trial start Phase 1/Phase 2: A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. source ↗
Sep 17, 2024 Raise Series A · $68M source ↗

Upcoming milestones

2027-04 (ESTIMATED) · Phase 1/Phase 2 · A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis. · NCT07369076

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT07369076	A Clinical Trial to Evaluate NB-4746 in Participants With Amyotrophic Lateral Sclerosis.	Phase 1/Phase 2	Recruiting	Mar 4, 2026	2027-04 (estimated)